Detalhe da pesquisa
1.
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma.
Blood
; 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38728378
2.
Comparison of Infectious Complications with BCMA-directed Therapies in Multiple Myeloma.
Res Sq
; 2024 Feb 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38405866
3.
CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma.
Blood Adv
; 8(7): 1600-1611, 2024 Apr 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-37878808
4.
Patterns of CRS with Teclistamab in Relapsed/Refractory Multiple Myeloma patients with Prior T-Cell Redirection Therapy.
Blood Adv
; 2024 Apr 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38598713
5.
Sustained Minimal Residual Disease Negativity in Multiple Myeloma is Associated with Stool Butyrate and Healthier Plant-Based Diets.
Clin Cancer Res
; 28(23): 5149-5155, 2022 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36170461
6.
Safety and Effectiveness of Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma: The MANHATTAN Nonrandomized Clinical Trial.
JAMA Oncol
; 7(6): 862-868, 2021 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33856405
7.
A short course of daratumumab in patients with multiple myeloma and minimal residual disease after induction therapy.
Leuk Lymphoma
; 63(14): 3488-3492, 2022 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-36282633